@article{d7c3ce8bed624332a813dac23e46897f,
title = "QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care",
abstract = "The use of corrected QT (QTc) interval-prolonging medications is a common exclusion criterion in clinical trials. To explore its potential effect, a cohort of patients with lung cancer in the Veterans Affairs system was studied to determine the prevalence of such drugs. Among 280,068 patients, 28.4% had been prescribed ≥1 QTc-interval prolonging medication, and 7.3% had been prescribed ≥2, warranting further research into the actual clinical risks and optimal management of QTc-prolonging medications in populations with cancer.",
keywords = "Clinical research, Exclusion criteria, Oncocardiology, Targeted therapy, Thoracic oncology",
author = "Tri Le and Hui Yang and Sawsan Rashdan and Link, {Mark S.} and Zaha, {Vlad G.} and Carlos Alvarez and Gerber, {David E.}",
note = "Funding Information: The present study was supported in part by a National Cancer Institute (NCI) Midcareer Investigator Award in Patient-Oriented Research (grant K24 CA201543-01 to D.E.G.), the NCI Small Grants Program for Cancer Research (grant 1R03CA191875, to D.E.G.), an NCI National Clinical Trials Network Lead Academic Performance Site Award (grant 5U10CA180870 to D.E.G.), National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award (grant K08 DK101602 to C.A.A.), the UT Southwestern Center for Translational Medicine (grant UL1 TR001105 to C.A.A.), and the Cancer Prevention and Research Institute of Texas (grant CPRIT 50C1324901 to V.G.Z.). The authors thank Ms Dru Gray for providing assistance with manuscript preparation, and Helen Mayo, MLS, for providing assistance with literature searches. Funding Information: The present study was supported in part by a National Cancer Institute (NCI) Midcareer Investigator Award in Patient-Oriented Research (grant K24 CA201543-01 to D.E.G.), the NCI Small Grants Program for Cancer Research (grant 1R03CA191875 , to D.E.G.), an NCI National Clinical Trials Network Lead Academic Performance Site Award (grant 5U10CA180870 to D.E.G.), National Institute of Diabetes and Digestive and Kidney Diseases Career Development Award (grant K08 DK101602 to C.A.A.), the UT Southwestern Center for Translational Medicine (grant UL1 TR001105 to C.A.A.), and the Cancer Prevention and Research Institute of Texas (grant CPRIT 50C1324901 to V.G.Z.). The authors thank Ms Dru Gray for providing assistance with manuscript preparation, and Helen Mayo, MLS, for providing assistance with literature searches. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",
year = "2020",
month = jan,
doi = "10.1016/j.cllc.2019.07.008",
language = "English (US)",
volume = "21",
pages = "21--27.e5",
journal = "Clinical lung cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",
}